Wassim Chemaitilly1,2, Thomas E Merchant3, Zhenghong Li2, Nicole Barnes1, Gregory T Armstrong2,4, Kirsten K Ness2, Ching-Hon Pui5, Larry E Kun3, Leslie L Robison2, Melissa M Hudson2,4, Charles A Sklar6, Amar Gajjar5. 1. Division of Endocrinology, Department of Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, USA. 2. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA. 3. Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. 4. Division of Cancer Survivorship, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 5. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 6. Department of Pediatrics, Memorial - Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
OBJECTIVES: To estimate the prevalence of central precocious puberty (CPP) after treatment for tumours and malignancies involving the central nervous system (CNS) and examine repercussions on growth and pubertal outcomes. DESIGN: Retrospective study of patients with tumours near and/or exposed to radiotherapy to the hypothalamus/pituitary axis (HPA). PATIENTS AND MEASUREMENTS: Patients with CPP were evaluated at puberty onset, completion of GnRH agonist treatment (GnRHa) and last follow-up. Multivariable analysis was used to test associations between tumour location, sex, age at CPP, GnRHa duration and a diagnosis of CPP with final height <-2SD score (SDS), gonadotropin deficiency (LH/FSHD) and obesity, respectively. RESULTS: Eighty patients (47 females) had CPP and were followed for 11·4 ± 5·0 years (mean ± SD). The prevalence of CPP was 15·2% overall, 29·2% following HPA tumours and 6·6% after radiotherapy for non-HPA tumours. Height <-2SDS was more common at the last follow-up than at the puberty onset (21·4% vs 2·4%, P = 0·005). Obesity was more prevalent at the last follow-up than at the completion of GnRHa or the puberty onset (37·7%, 22·6% and 20·8%, respectively, P = 0·03). Longer duration of GnRHa was associated with increased odds of final height <-2SDS (OR = 2·1, 95% CI 1·0-4·3) and longer follow-up with obesity (OR = 1·3, 95% CI 1·1-1·6). LH/FSHD was diagnosed in 32·6%. There was no independent association between CPP and final height <-2SDS, and LH/FSHD and obesity in the subset of patients with HPA low-grade gliomas. CONCLUSIONS: Patients with organic CPP experience an incomplete recovery of growth and a high prevalence of LH/FSHD and obesity. Early diagnosis and treatment of CPP may limit further deterioration of final height prospects.
OBJECTIVES: To estimate the prevalence of central precocious puberty (CPP) after treatment for tumours and malignancies involving the central nervous system (CNS) and examine repercussions on growth and pubertal outcomes. DESIGN: Retrospective study of patients with tumours near and/or exposed to radiotherapy to the hypothalamus/pituitary axis (HPA). PATIENTS AND MEASUREMENTS: Patients with CPP were evaluated at puberty onset, completion of GnRH agonist treatment (GnRHa) and last follow-up. Multivariable analysis was used to test associations between tumour location, sex, age at CPP, GnRHa duration and a diagnosis of CPP with final height <-2SD score (SDS), gonadotropin deficiency (LH/FSHD) and obesity, respectively. RESULTS: Eighty patients (47 females) had CPP and were followed for 11·4 ± 5·0 years (mean ± SD). The prevalence of CPP was 15·2% overall, 29·2% following HPA tumours and 6·6% after radiotherapy for non-HPA tumours. Height <-2SDS was more common at the last follow-up than at the puberty onset (21·4% vs 2·4%, P = 0·005). Obesity was more prevalent at the last follow-up than at the completion of GnRHa or the puberty onset (37·7%, 22·6% and 20·8%, respectively, P = 0·03). Longer duration of GnRHa was associated with increased odds of final height <-2SDS (OR = 2·1, 95% CI 1·0-4·3) and longer follow-up with obesity (OR = 1·3, 95% CI 1·1-1·6). LH/FSHD was diagnosed in 32·6%. There was no independent association between CPP and final height <-2SDS, and LH/FSHD and obesity in the subset of patients with HPA low-grade gliomas. CONCLUSIONS:Patients with organic CPP experience an incomplete recovery of growth and a high prevalence of LH/FSHD and obesity. Early diagnosis and treatment of CPP may limit further deterioration of final height prospects.
Authors: Wassim Chemaitilly; Zhenghong Li; Sujuan Huang; Kirsten K Ness; Karen L Clark; Daniel M Green; Nicole Barnes; Gregory T Armstrong; Matthew J Krasin; Deo Kumar Srivastava; Ching-Hon Pui; Thomas E Merchant; Larry E Kun; Amar Gajjar; Melissa M Hudson; Leslie L Robison; Charles A Sklar Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544
Authors: Robert H Lustig; Susan R Post; Kleebsabai Srivannaboon; Susan R Rose; Robert K Danish; George A Burghen; Xiaoping Xiong; Shengjie Wu; Thomas E Merchant Journal: J Clin Endocrinol Metab Date: 2003-02 Impact factor: 5.958
Authors: Gregory T Armstrong; John A Whitton; Amar Gajjar; Larry E Kun; Eric J Chow; Marilyn Stovall; Wendy Leisenring; Leslie L Robison; Charles A Sklar Journal: Cancer Date: 2009-06-01 Impact factor: 6.860
Authors: Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Celia Chao; Steve G Widen; Thomas G Wood; John R Zatarain; Paul Johnson; Aakash Gajjar; Guillermo Gomez; Suimin Qiu; Jill Thompson; Heidi Spratt; Mark R Hellmich Journal: Anticancer Res Date: 2017-07 Impact factor: 2.480
Authors: Laura van Iersel; Zhenghong Li; Deo Kumar Srivastava; Tara M Brinkman; Kari L Bjornard; Carmen L Wilson; Daniel M Green; Thomas E Merchant; Ching-Hon Pui; Rebecca M Howell; Susan A Smith; Gregory T Armstrong; Melissa M Hudson; Leslie L Robison; Kirsten K Ness; Amar Gajjar; Kevin R Krull; Charles A Sklar; Hanneke M van Santen; Wassim Chemaitilly Journal: J Clin Endocrinol Metab Date: 2019-12-01 Impact factor: 5.958